Table 1.
Relevant baseline characteristics of evaluable patient cohorts constructed to model thrombotic and evolutionary hazards by using GBTM
| Characteristic | Value |
|---|---|
| Thrombosis | |
| Patients, n | 377 |
| Age at diagnosis, y | |
| Median (minimum-maximum) | 58 (20-93) |
| Male, n (%) | 181 (48) |
| Duration of disease prior to contact, mo | |
| Median (minimum-maximum) | 2 (0-358) |
| Prior thrombosis, n (%) | 93 (25) |
| Number of cardiovascular risk factors (median) | 1 |
| Diabetes, n (%) | 38 (10) |
| Hypertension, n (%) | 151 (40) |
| Hyperlipidemia, n (%) | 90 (24) |
| Coronary artery disease, n (%) | 36 (10) |
| History of smoking, n (%) | 97 (26) |
| Follow-up, mo | |
| Median (minimum-maximum) | 48 (12-249) |
| Period of phlebotomy-only during trajectory period, n (%) | 118 (31) |
| On aspirin during trajectory period, n (%) | 340 (90) |
| On hydroxyurea during trajectory period, n (%) | 226 (60) |
| On ruxolitinib during trajectory period, n (%) | 40 (11) |
| On peg-IFN-α2a during trajectory period, n (%) | 34 (9) |
| Evolution | |
| Patients, n | 378 |
| Age at diagnosis | |
| Median (y) | 58 (20-93) |
| Duration of disease (prior to contact), mo | |
| Median (minimum-maximum) | 1 (0-358) |
| Follow-up, mo | |
| Median (minimum-maximum) | 48 (12-193) |
| Period of phlebotomy-only during trajectory period, n (%) | 120 (32) |
| On aspirin during trajectory period, n (%) | 341 (90) |
| On hydroxyurea during trajectory period, n (%) | 223 (59) |
| On ruxolitinib during trajectory period, n (%) | 38 (10) |
| On peg-IFN-α2a during trajectory period, n (%) | 34 (9) |